Aspects of Russia's drug sovereignty in terms of anti-tuberculosis drugs production

Introduction. Tuberculosis is still an unresolved medical problem in Russia. Therefore, the issue of providing Russian patients with anti-tuberculosis drugs is extremely relevant. Purpose of the study. To analyze the Russian production of anti-tuberculosis drugs, focusing on the country of origin of the pharmaceutical substance (PS). Materials and methods. Using articles, reports, special databases, and the latest WHO recommendations on tuberculosis therapy, the authors showed the origin of pharmaceutical substances, which are used to produce the dosage form (DF) of anti-tuberculosis drugs in Russia. Results. The aspects of industrial provision of Russia with anti-tuberculosis drugs are outlined. The Russian anti-tuberculosis drugs manufacturers (PS and DF) as well as foreign suppliers of PS to Russia are analyzed. Out of 22 types of antibiotics, 5 are produced from imported PS only, 13 are produced from imported and domestic PS, 2 are not produced in Russia but allowed for import, 2 are not registered in Russia. In the production of 13 types of antibiotics, the share of PS suppliers from Russia does not exceed 27 %. The share of foreign suppliers of PS for DF production in Russia is: India (5-100 % for different PS), China (3-81 %), Israel (4 %), Republic of Korea (7-63.5 %), Taiwan (3 %), Thailand (20-40 %), EU (3-100 %). Conclusion. Based on the results, a conclusion was made about vulnerability of Russian healthcare system in terms of tuberculosis treatment. For implementation the drug sovereignty strategy, further actions are needed to localize the production cycle of anti-tuberculosis drugs on the Russian territory.